Scopus Biopharma, Inc. (SCPS)

NASDAQ: SCPS · IEX Real-Time Price · USD
0.242
-0.002 (-0.62%)
Sep 30, 2022 4:00 PM EDT - Market closed
-0.62%
Market Cap 5.11M
Revenue (ttm) n/a
Net Income (ttm) -15.90M
Shares Out 21.09M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,667
Open 0.243
Previous Close 0.244
Day's Range 0.231 - 0.248
52-Week Range 0.210 - 4.280
Beta n/a
Analysts Buy
Price Target 12.24 (+4,955.8%)
Earnings Date n/a

About SCPS

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhi... [Read more...]

Industry Biotechnology
IPO Date Dec 16, 2020
Employees 9
Stock Exchange NASDAQ
Ticker Symbol SCPS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SCPS stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 4,955.76% from the latest price.

Price Target
$12.24
(4,955.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma

4 months ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies S...

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology

6 months ago - GlobeNewsWire

Scopus BioPharma Provides Update Following Annual Meeting of Stockholders

Overwhelming Majority of Shares Voted by Unaffiliated Stockholders were in Favor of Scopus' Director Nominees

8 months ago - GlobeNewsWire

DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC.

NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.00...

8 months ago - PRNewsWire

Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster's Campaign Against the Company

Latest Legal Claims by Laster Actually Call into Question his Stock Ownership

9 months ago - GlobeNewsWire

Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company's Director Nominees on the WHITE P...

Company's Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies

9 months ago - GlobeNewsWire

Dr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual M...

NEW YORK and JERUSALEM, Dec. 6, 2021 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with the other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $...

9 months ago - PRNewsWire

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...

11 months ago - GlobeNewsWire

Scopus BioPharma to Present at the LD Micro Main Event

Scopus to present on the recent launch of Duet Therapeutics,  its wholly-owned subsidiary focused on immuno-oncology

11 months ago - GlobeNewsWire

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct...

1 year ago - GlobeNewsWire

Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference

Scopus to present on the recent launch of Duet Therapeutics,  its wholly-owned subsidiary focused on immuno-oncology

1 year ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Ann...

Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice

1 year ago - GlobeNewsWire

Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the ...

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...

1 year ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of ...

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...

1 year ago - GlobeNewsWire

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signifi...

1 year ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Ther...

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors

1 year ago - GlobeNewsWire

China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 In...

New patent covers compound and composition and methods of use for CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO)

1 year ago - GlobeNewsWire

Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Bo...

JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.

Other symbols: XTLB
1 year ago - PRNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scie...

Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope Natio...

1 year ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Pr...

1 year ago - GlobeNewsWire

What Is Happening With Scopus BioPharma Stock On Thursday?

Scopus BioPharma Inc (NASDAQ: SCPS) has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune. Related Content: Scopus Bio...

1 year ago - Benzinga

Scopus BioPharma Launches Duet Therapeutics

Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021

1 year ago - GlobeNewsWire

Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...

1 year ago - GlobeNewsWire

Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune

Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics

1 year ago - GlobeNewsWire

Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders

NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company's 2021 Annual Meeting of Stockholders (“2021 Ann...

1 year ago - GlobeNewsWire